Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Roschke Website

Anna V. Roschke, Ph.D.

Selected Publications

1)  Affer M, Chesi M, Chen WD, Keats JJ, Demchenko YN, Roschke AV, Van Wier S, Fonseca R, Bergsagel PL, Kuehl WM.
Promiscuous rearrangements of the MYC locus hijack enhancers and super-enhancers to dysregulate MYC expression in multiple myeloma.
Leukemia. 2014.
2)  Kim GY, Gabrea A, Demchenko YN, Bergsagel L, Roschke AV, Kuehl WM.
Complex IGH rearrangements in multiple myeloma: Frequent detection discrepancies among three different probe sets.
Genes Chromosomes Cancer. 2014.
3)  Roschke AV, Rozenblum E.
Multi-Layered Cancer Chromosomal Instability Phenotype.
Front Oncol. 3: 302, 2013.
4)  Klorin G, Rozenblum E, Glebov O, Walker RL, Park Y, Meltzer PS, Kirsch IR, Kaye FJ, Roschke AV.
Integrated high-resolution array CGH and SKY analysis of homozygous deletions and other genomic alterations present in malignant mesothelioma cell lines.
Cancer Genet. 206: 191-205, 2013.
5)  Cheng Y, Zhang Z, Keenan B, Roschke AV, Nakahara K, Aplan PD.
Efficient repair of DNA double-strand breaks in malignant cells with structural instability.
Mutat. Res. 683: 115-22, 2010.
6)  Roschke AV, Kirsch IR.
Targeting karyotypic complexity and chromosomal instability of cancer cells.
Curr Drug Targets. 11: 1341-50, 2010.
7)  Roschke AV, Glebov OK, Lababidi S, Gehlhaus KS, Weinstein JN, Kirsch IR.
Chromosomal instability is associated with higher expression of genes implicated in epithelial-mesenchymal transition, cancer invasiveness, and metastasis and with lower expression of genes involved in cell cycle checkpoints, DNA repair, and chromatin maintenance.
Neoplasia. 10: 1222-30, 2008.
8)  Gabrea A, Martelli ML, Qi Y, Roschke A, Barlogie B, Shaughnessy JD, Sawyer JR, Kuehl WM.
Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors.
Genes Chromosomes Cancer. 47: 573-90, 2008.
9)  Lenz G, Nagel I, Siebert R, Roschke AV, Sanger W, Wright GW, Dave SS, Tan B, Zhao H, Rosenwald A, Muller-Hermelink HK, Gascoyne RD, Campo E, Jaffe ES, Smeland EB, Fisher RI, Kuehl WM, Chan WC, Staudt LM.
Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma.
J. Exp. Med. 204: 633-43, 2007.
10)  Bussey KJ, Chin K, Lababidi S, Reimers M, Reinhold WC, Kuo WL, Gwadry F, Kouros-Mehr H, Fridlyand J, Jain A, Collins C, Nishizuka S, Tonon G, Roschke A, Gehlhaus K, Kirsch I, Scudiero DA, Gray JW, Weinstein JN.
Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel.
Mol. Cancer Ther. 5: 853-67, 2006.
11)  Wallqvist A, Huang R, Covell DG, Roschke AV, Gelhaus KS, Kirsch IR.
Drugs aimed at targeting characteristic karyotypic phenotypes of cancer cells.
Mol. Cancer Ther. 4: 1559-68, 2005.
12)  Roschke AV, Lababidi S, Tonon G, Gehlhaus KS, Bussey K, Weinstein JN, Kirsch IR.
Karyotypic "state" as a potential determinant for anticancer drug discovery.
Proc. Natl. Acad. Sci. U.S.A. 102: 2964-9, 2005.
13)  Roschke AV, Kirsch IR.
Targeting cancer cells by exploiting karyotypic complexity and chromosomal instability.
Cell Cycle. 4: 679-82, 2005.
14)  Reinhold WC, Kouros-Mehr H, Kohn KW, Maunakea AK, Lababidi S, Roschke A, Stover K, Alexander J, Pantazis P, Miller L, Liu E, Kirsch IR, Urasaki Y, Pommier Y, Weinstein JN.
Apoptotic susceptibility of cancer cells selected for camptothecin resistance: gene expression profiling, functional analysis, and molecular interaction mapping.
Cancer Res. 63: 1000-11, 2003.
15)  Roschke AV, Tonon G, Gehlhaus KS, McTyre N, Bussey KJ, Lababidi S, Scudiero DA, Weinstein JN, Kirsch IR.
Karyotypic complexity of the NCI-60 drug-screening panel.
Cancer Res. 63: 8634-47, 2003.
16)  Roschke AV, Stover K, Tonon G, Schaffer AA, Kirsch IR.
Stable karyotypes in epithelial cancer cell lines despite high rates of ongoing structural and numerical chromosomal instability.
Neoplasia. 4: 19-31, 2002.
17)  Shou Y, Martelli ML, Gabrea A, Qi Y, Brents LA, Roschke A, Dewald G, Kirsch IR, Bergsagel PL, Kuehl WM.
Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma.
Proc. Natl. Acad. Sci. U.S.A. 97: 228-33, 2000.
18)  Blegen H, Einhorn N, Sjövall K, Roschke A, Ghadimi BM, McShane LM, Nilsson B, Shah K, Ried T, Auer G.
Prognostic significance of cell cycle proteins and genomic instability in borderline, early and advanced stage ovarian carcinomas.
Int. J. Gynecol. Cancer. 10: 477-487, 2000.
19)  Tonon G, Roschke A, Stover K, Shou Y, Kuehl WM, Kirsch IR.
Spectral karyotyping combined with locus-specific FISH simultaneously defines genes and chromosomes involved in chromosomal translocations.
Genes Chromosomes Cancer. 27: 418-23, 2000.
20)  Chong SS, Pack SD, Roschke AV, Tanigami A, Carrozzo R, Smith AC, Dobyns WB, Ledbetter DH.
A revision of the lissencephaly and Miller-Dieker syndrome critical regions in chromosome 17p13.3.
Hum. Mol. Genet. 6: 147-55, 1997.
21)  Chong SS, Tanigami A, Roschke AV, Ledbetter DH.
14-3-3 epsilon has no homology to LIS1 and lies telomeric to it on chromosome 17p13.3 outside the Miller-Dieker syndrome chromosome region.
Genome Res. 6: 735-41, 1996.
22)  Ning Y, Roschke A, Smith A, Macha M, Precht K, Riethman H, Ledbetter D, Flint J, Horsley S, Regan R, Kearney L, Knight S, Kvaloy K, Brown W.
A complete set of human telomeric probes and their clinical application.
Nat Genet. 14: 86-9, 1996.
23)  Ning Y, Roschke A, Christian SL, Lesser J, Sutcliffe JS, Ledbetter DH.
Identification of a novel paternally expressed transcript adjacent to snRPN in the Prader-Willi syndrome critical region.
Genome Res. 6: 742-6, 1996.
Click Here to View Collapsed Bibliography.

This page was last updated on 3/21/2014.